Pooja Prasad, MD @poojaprasad91 X Profile

Pooja Prasad, MD

@poojaprasad91

Followers

603

Following

2K

Media

94

Statuses

630

@UCSF AHFTC fellow, a sailor in my dreams @cardionerds #FIT #WIC @wellesleyalums @URochester_SMD @UCD_IM @OHSUCardFellows

Portland, Oregon

Joined December 2011

Don't wanna be here? Send us removal request.

Amit Goyal MD MAS

@AmitGoyalMD

8 months

🔗 https://t.co/iapjpzV9jz @poojaprasad91 @CaliRClark @AKBhatiaMD @

uscjournal.com

Heart failure (HF) is a global health issue, contributing significantly to morbidity and mortality, particularly in North America. The management of HF is complex, requiring diligent monitoring

0

1

2

Women As One

@WomenAs1

6 months

🔬 Mentorship Pairing #2, sponsored by @BridgeBioPharma, winners announced! Congratulations to @poojaprasad91 & @HannaGaggin who will delve into critical aspects of ATTR-CM research through their collaborative project over the next 12 months. #WomenAsOneAwards #WIC

1

6

29

Daniel Ambinder, MD

@Dr_DanMD

10 months

🍼 405. @CardioNerds Case Report: Like Mother, Like Son 💗Explore a case of peripartum cardiomyopathy & infantile HCM unifying a diagnosis💗 Feat: Drs. @achdoctmoe @HarrisonJVDMD, Sri Nayak & Donny Mattia, @poojaprasad91 ‼️ @MayoAZCVFellows Link below👇👇👇

3

9

27

Jackie DesJardin, MD

@JTDesJardin

2 years

@mitralarcade (@UTSWMedCenter) presents on 41W w/ deafness who underwent HM3 w/ use of haptic devices (bed shaker, pager, smartwatch) to ensure detection of LVAD alarms. Kathleen Grady (@NorthwesternMed) emphasizes need to optimize access, safety, personalization in LVAD

1

3

5

Jackie DesJardin, MD

@JTDesJardin

2 years

Great session on early career and trainee clinical case dilemmas, loved the pairing of trainee clinical case + expert discussant. A little bit of everything 🫀🫁 ⚙️ #HeartTransplant #LungTransplant #MCS #LVAD #PVD #PAH

1

2

5

Jackie DesJardin, MD

@JTDesJardin

2 years

@SebHascoet (@HMLannelongue) PRO for transcutaneous shunts,🎈septostomy outcomes improving, ⬇️RAP, ⬆️CI, helps symptoms, patency better w/ atrial flow regulators. Re: Potts TC options game-changing, easy when PDA present, still feasible w/o PDA & new devices in development

1

2

Jackie DesJardin, MD

@JTDesJardin

2 years

David Morales (@CincyChildrens) CON for transcutaneous shunts. Data for atrial septostomy old and limited in kids. Surgical Potts pts come off IV prostanoids, better outcomes than lung txplt. Registries of TC-Potts a/w worse outcomes, complicates/limits eventual txplt

0

1

Jackie DesJardin, MD

@JTDesJardin

2 years

@3rdheartsound notes biomarkers in CAV not currently guideline-recommended, but several metabolic (TChol, TGs), inflammatory (CRP), proteomic, circulating microRNAs, immunologic (Class II DSAs, GEP), injury markers (BNP, troponin, ddcfDNA) all have been associated with CAV

1

3

6

Jackie DesJardin, MD

@JTDesJardin

2 years

Lindsey Aurora outlines txt and prevention: aspirin (RCT AERIAL TBD), early PSI/mTOR, LDL control (aim <100 or <50 if CAV present). PCSK9i safe & effective post-OHT. Redo OHT for grade 3 more advantageous if LV dysfunction present. In the future: Belatecept? tocilizumab? SGLT2i?

1

3

Jackie DesJardin, MD

@JTDesJardin

2 years

Guillaume Coutance discusses that the natural history of CAV has 4 major trajectories (none, mild/late, severe/late, and severe/early). Invasive biomarkers and predictive models will one day help us define patients’ trajectories

0

1

Jackie DesJardin, MD

@JTDesJardin

2 years

Tor Clemmensen takes us through CAV pathogenesis: Step 1 endothelial injury and dysfunction (relating to donor, recipient, and surgical factors); Step 2 smooth muscle cell proliferation (CMV infection, DSAs).. much yet to be known

1

3

Jackie DesJardin, MD

@JTDesJardin

2 years

Kicking off the PH content @ISHLT with an in depth session on Coming together: improving survival in PAH! #ISHLT2024

1

2

8

Jackie DesJardin, MD

@JTDesJardin

2 years

@SophiaAirhartMD discusses risk assessment in adults with PAH: achieving low risk status ASAP is key to improved 1 year survival, utilization of risk assessment remains low.

1

2

Jackie DesJardin, MD

@JTDesJardin

2 years

Allen Everett reviews the development and implementation of a risk assessment model in pediatric PAH patients in PPHNet, with validation against Dutch and Spanish registries.

0

1

2

Jackie DesJardin, MD

@JTDesJardin

2 years

@IsaOpitz on f/u. Persistent PH after PEA common (25%), PVR>5 a/w worse survival. Re-assess at 3-6 mo, RHC needed. Target FC I-II & normalize resting hemodynamics. Need for standardized f/u schemes. Echo/ NTproBNP (>300) at 6mo may help (some missed cases), early data on microRNA

0

2

1

Jackie DesJardin, MD

@JTDesJardin

2 years

Marc de Perrot on interventions. PEA for segmental dz, but BPA+meds beneficial. RACE & MR BPA RCTs (BPA vs rio in non-surgical)– BPA w/ better hemodynamics but adverse events. PEA risk driven by RV failure, VA-ECMO to bridge to recovery after PEA beneficial

1

Jackie DesJardin, MD

@JTDesJardin

2 years

Rise and shine! ☀️ Early birds at #ISHLT2024 caught the worm with a groundbreaking session on CTEPH. #PVD #CTEPH #SunriseScience

1

2

Jackie DesJardin, MD

@JTDesJardin

2 years

In a post-hoc analysis of STELLAR and PULSAR, @mardigomberg stratified pts by cardiac index (cutoff of 2 or 2.5) & sotatercept improved 6MWD, PVR, NTproBNP, echo parameters (RVEF, TAPSE/SPAP), WHO-FC in all CI subgroups. Similar safety across CIs

0

1

Jackie DesJardin, MD

@JTDesJardin

2 years

@RaymondBenzaMD's analysis of TORREY compared risk tools (REVEAL 2.0 & Lite 2, COMPERA 2.0, Non-invasive French), showed seralutinib favorably shifted risk scores at 24 wks. COMPERA 2.0 significantly improved (OR 9.32, p<0.05), REVEAL 2.0 and French w/ trend

1

Jackie DesJardin, MD

@JTDesJardin

2 years

🚀 Dive into the primary data with 'What’s New in Pulmonary Vascular Disease' - the latest updates from registries and clinical trials moderated by @MarcSimonMD @mardigomberg #ISHLT2024 #PAH #PVD

1

6